Lonvoguran ziclumeran

The randomized comparison enrolled 80 participants, with 52 receiving lonvo-z and 28 receiving placebo. Median follow-up was 7.5 months. This follow-up does not establish lifetime durability or exclude uncommon delayed adverse effects. Attack data after initiation of long-term prophylaxis were excluded from the reported attack-rate analysis. Week 28 AE-QoL data were available for 44 participants receiving lonvo-z and 20 receiving placebo, fewer than the randomized populations. The placebo-controlled design does not establish comparative effectiveness against an active prophylactic treatment. Eligibility excluded HAE with normal C1 inhibitor.

Phase 1 was open-label and included 10 participants across three dose cohorts. Phase 2 randomized 27 participants, including six assigned to placebo. The reported confidence intervals for the differences in monthly attack rate versus placebo crossed zero, so the point estimates alone do not demonstrate a statistically conclusive difference. The AE-QoL analysis included only participants with paired assessments and had nine, nine, and four participants in the 25-mg, 50-mg, and placebo groups, respectively. The pooled 50-mg analyses combine phase 1/2 and long-term follow-up observations. Becoming attack-free and prophylaxis-free during follow-up is not the same outcome as remaining attack-free throughout follow-up. Seven participants had less than six months of follow-up after becoming attack-free and prophylaxis-free. These pooled observations do not establish lifetime durability.

The separately identified long-term follow-up safety subgroup included 17 participants previously treated with 50 mg. The presentation reported no serious adverse events or treatment-related adverse events in that subgroup. The attack-free results in the same presentation combine parent-study and long-term follow-up observations and should not be interpreted as an independent 17-participant efficacy analysis. The subgroup size does not exclude uncommon delayed adverse effects.

The randomized groups included 125 participants in total, and 113 (90.4%) completed the study. The 26-week placebo-controlled comparison describes repeated lanadelumab prophylaxis, not a comparison with lonvo-z. Differences between the trials in treatment schedules and observation periods prevent the reported attack rates from establishing comparative superiority.

The study treated 90 participants, with 45 receiving donidalorsen every four weeks, 23 receiving it every eight weeks, and 22 receiving placebo. The full analysis set required at least one dose, rather than including every randomized participant regardless of exposure. The evidence describes a 24-week placebo-controlled comparison of repeated prophylaxis and does not directly compare donidalorsen with lonvo-z. The smaller every-eight-week and placebo groups limit precision for uncommon adverse events.

Of 65 randomized participants, 64 were included in the reported comparison after one participant was randomized in error. The six-month trial compared monthly garadacimab with placebo, not with lonvo-z. Its group sizes of 39 and 25 participants limit precision for uncommon adverse events. The results should not be used as a head-to-head comparison with a one-time gene-editing treatment.

The study randomized 121 participants and treated 120. The efficacy population was intent-to-treat, whereas the reported treated populations included 41 participants receiving 110 mg, 40 receiving 150 mg, and 39 receiving placebo. The 24-week comparison evaluates ongoing oral prophylaxis and does not provide a direct comparison with lonvo-z. The absence of drug-related serious adverse events in this sample does not exclude uncommon risks.

The crossover study randomized 90 participants, and 79 completed it. Efficacy was evaluated during the last 14 weeks of each treatment period, rather than the entire 32-week study. The findings concern repeated subcutaneous C1 inhibitor prophylaxis versus placebo within a crossover design. They do not establish comparative effectiveness against lonvo-z, which was evaluated in a parallel-group, single-infusion trial.